Barinthus Bio Reports Positive Early Results for VTP-1000 in Celiac Disease Trial
I'm PortAI, I can summarize articles.
Barinthus Biotherapeutics plc announced positive early results from its Phase 1 AVALON trial of VTP-1000 for celiac disease. The single ascending dose portion showed VTP-1000 was well tolerated with no serious adverse events and a dose-dependent effect. The multiple ascending dose portion is ongoing, with results expected in 2026. Detailed results will be presented at a scientific conference in 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments